Cargando…
Immunotherapy of liver cancer with hepcortespenlisimut-L: open-label Phase II clinical study in patients with advanced HCC
Autores principales: | Tarakanovskaya, Marina G, Chinburen, Jigjidsuren, Purevsuren, Genden, Munkhzaya, Chogsom, Batchuluun, Purev, Bat-Ireedui, Purev, Dandii, Dorjiin, Oyungerel, Dandii, Kutsyna, Galyna A, Bain, Allen I, Jirathitikal, Vichai, Bourinbaiar, Aldar S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649454/ http://dx.doi.org/10.1186/2051-1426-3-S2-P200 |
Ejemplares similares
-
Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L
por: Tarakanovskaya, Marina G, et al.
Publicado: (2017) -
Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study
por: Bourinbaiar, Aldar S, et al.
Publicado: (2010) -
Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
por: Metadilogkul, Orapun, et al.
Publicado: (2009) -
Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia
por: Bourinbaiar, Aldar, et al.
Publicado: (2010) -
Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB
por: Butov, Dmitry A, et al.
Publicado: (2011)